Collegium Pharmaceutical (COLL) vs Inventiva S.A. American Depository Shares (IVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Collegium Pharmaceutical (COLL) has outperformed Inventiva S.A. American Depository Shares (IVA) over the past year, losing 33.5% versus a loss of 42.9%. Over five years, COLL leads with a +5.3% price change compared with -76.4% for IVA. Inventiva S.A. American Depository Shares is the larger company by market cap ($746.5 million vs $719.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COLL | IVA |
|---|---|---|
| Share price | $22.09 | $3.16 |
| Market cap | $719.15M | $746.46M |
| 1-day change | -0.09% | -4.82% |
| YTD return | -52.29% | -32.04% |
| 1-year return | -33.48% | -42.86% |
| 5-year return | +5.29% | -76.42% |
| P/E ratio (TTM) | 17.39 | — |
| Forward P/E | 3.33 | — |
| EPS (TTM) | $1.27 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.79 | $7.98 |
| 52-week low | $21.43 | $3.11 |
| Distance from 52-week high | -56.50% | -60.42% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +121.82% | +381.01% |
| Average volume | 749.33K | 1.40M |
| Shares outstanding | 32.56M | 236.22M |
| Employees | 423 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
About Inventiva S.A. American Depository Shares
IVA stock →Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
COLL vs IVA FAQ
Which is bigger, Collegium Pharmaceutical or Inventiva S.A. American Depository Shares?
Inventiva S.A. American Depository Shares (IVA) is larger, with a market capitalization of $746.46M compared with $719.15M for Collegium Pharmaceutical (COLL).
Which stock has performed better over the past year, COLL or IVA?
COLL returned -33.48% over the past 12 months, compared with -42.86% for IVA (price return, excluding dividends). Past performance does not predict future results.
Are Collegium Pharmaceutical and Inventiva S.A. American Depository Shares in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.